CRP and chronic kidney disease: Of the 4 CKD-DAMPs tested, Calprotectin was selected as a candidate for direct therapeutic blockade, as it consistently affected the pro-atherosclerotic functions tested in vitro, was further elevated in CVD-diagnosed CKD patients and highly correlated with the predictor of CV events CRP, suggesting a potential causal relationship between high Calprotectin levels and CVD in CKD patients.